Search results
20 cze 2024 · The current prostate cancer (PCa) screen test, prostate-specific antigen (PSA), has a high sensitivity for PCa but low specificity for high-risk, clinically significant PCa (csPCa), resulting...
25 wrz 2024 · Many studies have shown that men with an elevated PSA level and negative MRI results (i.e., a PI-RADS score of 1 or 2) still have a substantial risk of having clinically significant cancer ...
7 gru 2022 · We designed the randomized GÖTEBORG-2 trial to evaluate whether a screening algorithm that included PSA testing followed by targeted biopsy alone in patients with positive MRI results would ...
7 lis 2020 · Multiparametric magnetic resonance imaging (mpMRI) is a major tool for biopsy optimisation with pooled sensitivity and specificity of 0.91 (95% CI: 0.83–0.95) and 0.37 (95% CI: 0.29–0.46) for ISUP grade ≥2 cancers, and 0.95 (95% CI: 0.87–0.99) and 0.35 (95% CI: 0.26–0.46] for ISUP grade ≥3 cancers, respectively . MRI-TBx ...
6 lip 2021 · Methods. Two independent reviewers screen a systematic PubMed and Cochrane CENTRAL search for relevant articles (primary outcome: clinically significant cancer, index test: prostate MRI reading...
1 lip 2023 · The Early Detection of Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance in prostate cancer screening, initial and repeat biopsies, and biopsy technique.
22 mar 2024 · MCD tests are an appealing new paradigm in cancer screening in that they use a single, readily obtainable biospecimen to screen for more than one cancer concurrently, including lethal cancers for which there is no screening test available.
